ESTRO 2024 - Abstract Book

S5637

RTT - Patient experience and quality of life

ESTRO 2024

7. Talla, M., Nakum, B., & Abdul-Jalil, S. (2019). Potential Implications of Advanced Practice Radiography on the Canadian Healthcare System from Technologists Perspectives. MICH: The Student Journal of the Michener Institute of Education, 1(1).

276

Digital Poster

Two-year GI and GU toxicity results from prostate SABR treatment

Roeum Butt 1 , Angela Williams 1 , Prasana Nariyangadu 1 , Mariana Kroiss 2 , Daniel Megias 1

1 Mount Vernon Cancer Centre, Radiotherapy, Northwood, United Kingdom. 2 North Middlesex University Hospital, Radiotherapy, London, United Kingdom

Purpose/Objective:

This review aimed to investigate patient-reported outcome measures (PROMS) as per the Radiation Therapy Oncology Group (RTOG) & Common Terminology Criteria for Adverse Events (CTCAE) scale for patients who had stereotactic ablative body radiotherapy (SABR) to the prostate with MRI derived target volumes at a UK cancer center.

How the GI & GU toxicity compared against the reported toxicity results in the PACE-B trial [1] was further reviewed.

A secondary investigation was performed to see if the CTV-PTV margins used had an impact on PROMS.

Material/Methods:

The patients investigated were treated using a linear accelerator flattening filter-free (FFF) SABR technique. An MRI was used for target volume delineation and no fiducial markers were inserted. An isotropic CTV to PTV margin of 8mm was used except 4mm posteriorly. These margins differed from PACE B which used 5 mm isotropic and 3 mm posteriorly. A dose of 36.25Gy in 5# was delivered to all patients.

Toxicity results were obtained by the review radiographer team and were recorded on an in-house toxicity record matrix as per the RTOG (CTCAE) scale. Data was collected via a telephone follow-up call with patients.

The follow-up calls were conducted at 6 weeks to assess acute post-treatment side effects, 6 months to align with their first post-treatment PSA test, 1 year to align with their 2nd PSA test and 2 years to align with their 3rd PSA test post radiotherapy a further PSA is performed. The last PSA test is performed at 3 years before being discharged to their general practitioner, but toxicity results are not collected at this stage.

The descriptive values were converted via the inhouse toxicity matrix into their corresponding numbers for reported toxicity, to help ease of analysis.

Data collection was between 2020-2022 from a single institution. A total of 65 patients at 6 weeks, 32 at 6 months, 22 at 1 year and 5 at 2 years were analysed.